FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3082264620> ?p ?o ?g. }

• W3082264620 endingPage "1320" @default.
• W3082264620 startingPage "1306" @default.
• W3082264620 abstract "Duchenne muscular dystrophy (DMD) is a progressive muscle disease caused by the loss of dystrophin, which results in inflammation, fibrosis, and the inhibition of myoblast differentiation in skeletal muscle. Catalpol, an iridoid glycoside, improves skeletal muscle function by enhancing myogenesis; it has potential to treat DMD. We demonstrate the positive effects of catalpol in dystrophic skeletal muscle.mdx (loss of dystrophin) mice (n = 18 per group) were treated with catalpol (200 mg/kg) for six consecutive weeks. Serum analysis, skeletal muscle performance and histology, muscle contractile function, and gene and protein expression were performed. Molecular docking and ligand-target interactions, RNA interference, immunofluorescence, and plasmids transfection were utilized to explore the protective mechanism in DMD by which catalpol binding with transforming growth factor-β-activated kinase 1 (TAK1) in skeletal muscle.Six weeks of catalpol treatment improved whole-body muscle health in mdx mice, which was characterized by reduced plasma creatine kinase (n = 18, -35.1%, P < 0.05) and lactic dehydrogenase (n = 18, -10.3%, P < 0.05) activity. These effects were accompanied by enhanced grip strength (n = 18, +25.4%, P < 0.05) and reduced fibrosis (n = 18, -29.0% for hydroxyproline content, P < 0.05). Moreover, catalpol treatment protected against muscle fatigue and promoted muscle recovery in the tibialis anterior (TA) and diaphragm (DIA) muscles (n = 6, +69.8%, P < 0.05 and + 74.8%, P < 0.001, respectively), which was accompanied by enhanced differentiation in primary myoblasts from DMD patients (n = 6, male, mean age: 4.7 ± 1.9 years) and mdx mice. In addition, catalpol eliminated p-TAK1 overexpression in mdx mice (n = 12, -21.3%, P < 0.05) and primary myoblasts. The catalpol-induced reduction in fibrosis and increased myoblast differentiation resulted from the inhibition of TAK1 phosphorylation, leading to reduced myoblast trans-differentiation into myofibroblasts. Catalpol inhibited the phosphorylation of TAK1 by binding to TAK1, possibly at Asp-206, Thr-208, Asn-211, Glu-297, Lys-294, and Tyr-293.Our findings show that catalpol and TAK1 inhibitors substantially improve whole-body muscle health and the function of dystrophic skeletal muscles and may provide a novel therapy for DMD." @default.
• W3082264620 created "2020-09-08" @default.
• W3082264620 creator A5002705826 @default.
• W3082264620 creator A5003128598 @default.
• W3082264620 creator A5012706277 @default.
• W3082264620 creator A5045814483 @default.
• W3082264620 creator A5047954931 @default.
• W3082264620 creator A5049900943 @default.
• W3082264620 creator A5054049306 @default.
• W3082264620 creator A5055249391 @default.
• W3082264620 creator A5058165407 @default.
• W3082264620 creator A5073305217 @default.
• W3082264620 creator A5077886876 @default.
• W3082264620 creator A5085142676 @default.
• W3082264620 date "2020-08-31" @default.
• W3082264620 modified "2023-10-15" @default.
• W3082264620 title "A potential therapeutic effect of catalpol in Duchenne muscular dystrophy revealed by binding with TAK1" @default.
• W3082264620 cites W1987520160 @default.
• W3082264620 cites W1988616931 @default.
• W3082264620 cites W1997639385 @default.
• W3082264620 cites W2004740563 @default.
• W3082264620 cites W2020767700 @default.
• W3082264620 cites W2023829056 @default.
• W3082264620 cites W2031769119 @default.
• W3082264620 cites W2033924360 @default.
• W3082264620 cites W2052289997 @default.
• W3082264620 cites W2054888910 @default.
• W3082264620 cites W2078948729 @default.
• W3082264620 cites W2117938257 @default.
• W3082264620 cites W2147512364 @default.
• W3082264620 cites W2149697028 @default.
• W3082264620 cites W2166682935 @default.
• W3082264620 cites W2220172690 @default.
• W3082264620 cites W2255585558 @default.
• W3082264620 cites W2256214318 @default.
• W3082264620 cites W2265782222 @default.
• W3082264620 cites W2341026083 @default.
• W3082264620 cites W2343193821 @default.
• W3082264620 cites W2511362678 @default.
• W3082264620 cites W2576485312 @default.
• W3082264620 cites W2606840399 @default.
• W3082264620 cites W2735451781 @default.
• W3082264620 cites W2779917149 @default.
• W3082264620 cites W2784812244 @default.
• W3082264620 cites W2787073674 @default.
• W3082264620 cites W2790193086 @default.
• W3082264620 cites W2790562444 @default.
• W3082264620 cites W2797088273 @default.
• W3082264620 cites W2799427419 @default.
• W3082264620 cites W2885976578 @default.
• W3082264620 cites W2889488445 @default.
• W3082264620 cites W2892217681 @default.
• W3082264620 cites W2897298828 @default.
• W3082264620 cites W2898217822 @default.
• W3082264620 cites W2899653461 @default.
• W3082264620 cites W2903482897 @default.
• W3082264620 cites W2905440577 @default.
• W3082264620 cites W2907051747 @default.
• W3082264620 cites W2945900515 @default.
• W3082264620 cites W2982669953 @default.
• W3082264620 cites W2991041275 @default.
• W3082264620 doi "https://doi.org/10.1002/jcsm.12581" @default.
• W3082264620 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7567147" @default.
• W3082264620 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32869445" @default.
• W3082264620 hasPublicationYear "2020" @default.
• W3082264620 type Work @default.
• W3082264620 sameAs 3082264620 @default.
• W3082264620 citedByCount "18" @default.
• W3082264620 countsByYear W30822646202020 @default.
• W3082264620 countsByYear W30822646202021 @default.
• W3082264620 countsByYear W30822646202022 @default.
• W3082264620 countsByYear W30822646202023 @default.
• W3082264620 crossrefType "journal-article" @default.
• W3082264620 hasAuthorship W3082264620A5002705826 @default.
• W3082264620 hasAuthorship W3082264620A5003128598 @default.
• W3082264620 hasAuthorship W3082264620A5012706277 @default.
• W3082264620 hasAuthorship W3082264620A5045814483 @default.
• W3082264620 hasAuthorship W3082264620A5047954931 @default.
• W3082264620 hasAuthorship W3082264620A5049900943 @default.
• W3082264620 hasAuthorship W3082264620A5054049306 @default.
• W3082264620 hasAuthorship W3082264620A5055249391 @default.
• W3082264620 hasAuthorship W3082264620A5058165407 @default.
• W3082264620 hasAuthorship W3082264620A5073305217 @default.
• W3082264620 hasAuthorship W3082264620A5077886876 @default.
• W3082264620 hasAuthorship W3082264620A5085142676 @default.
• W3082264620 hasBestOaLocation W30822646201 @default.
• W3082264620 hasConcept C126322002 @default.
• W3082264620 hasConcept C134018914 @default.
• W3082264620 hasConcept C142724271 @default.
• W3082264620 hasConcept C181709278 @default.
• W3082264620 hasConcept C185592680 @default.
• W3082264620 hasConcept C204787440 @default.
• W3082264620 hasConcept C207200792 @default.
• W3082264620 hasConcept C2776160005 @default.
• W3082264620 hasConcept C2777488582 @default.
• W3082264620 hasConcept C2778943923 @default.
• W3082264620 hasConcept C2779030066 @default.
• W3082264620 hasConcept C2779959927 @default.

• next